RE:RE:RE:RE:RE:News AlertExcellent post, Bear. Thank you.
Interesting in that a basic requirement of patentability is usefulness. (If it is not useful, you can't patent something). In fact (and not surprisingly), that's the wording used by Pfizer in the wording of the patent, as follows:
"Other BET-family bromodomain inhibitors which are useful for the methods disclosed herein include, but are not limited to, the following BET-family bromodomain inhibitors"
(Emphasis added by me)
Hence, we have a statement here - by Pfizer no less - that the listed RVX and Zenith drugs (among others) are useful for the purposes of the patent.
When you think of it, that's pretty cool. Pfizer seems to be quite familiar with the compounds owned by both RVX and Zenith and has basically admitted that they are useful (at least for this new purpose....)
SF